Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $87.8 million.

  • Anika Therapeutics' Non-Current Assets fell 7.82% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year decrease of 7.82%. This contributed to the annual value of $89.1 million for FY2024, which is 16.99% down from last year.
  • Per Anika Therapeutics' latest filing, its Non-Current Assets stood at $87.8 million for Q3 2025, which was down 0.59% from $88.4 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Non-Current Assets peaked at $188.8 million during Q1 2021, and registered a low of $87.8 million during Q3 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $104.8 million (2024), whereas its average is $117.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first grew by 1.03% in 2023, then plummeted by 44.39% in 2024.
  • Anika Therapeutics' Non-Current Assets (Quarterly) stood at $179.0 million in 2021, then rose by 0.32% to $179.6 million in 2022, then crashed by 40.24% to $107.3 million in 2023, then fell by 16.99% to $89.1 million in 2024, then fell by 7.82% to $87.8 million in 2025.
  • Its Non-Current Assets was $87.8 million in Q3 2025, compared to $88.4 million in Q2 2025 and $88.1 million in Q1 2025.